Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P800002/S035

Avitene Microfibrillar Collagen Hemostat (MCH) Non-Woven Web

C.R. Bard, Inc. · Decision date Jul 15, 2026

FDA DECISIONP800002/S035

What did the FDA decide?

FDA records P800002/S035 as a supplement to PMA P800002, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jul 15, 2026.

FDA approval order statement

updated water system equipment for the Woburn, MA manufacturing site
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
General, Plastic Surgery
Decision date
Jul 15, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P800002/S035
Regulatory pathway
PMA supplement
Product code
LMF
Decision code
OK30
Decision date
Jul 15, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Agent, absorbable hemostatic, collagen based.

Product code
LMF
FDA device class
3

For the original device and its historical approval scope, see PMA P800002. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P800002 · Original PMA

    AVITENE MICROFIBRILLAR COLLAGEN HEMOSTAT NON-WOVEN WEB

  2. P800002/S035 received

    Application receipt date recorded by FDA.

  3. P800002/S035 · FDA decision

    30-Day Notice

  4. P800002/S036 · Related supplement

    Avitene Microfibrillar Collagen Hemostat (MCH) Non-Woven Web Webber

Timeline entries are records held by MedtechLedger for P800002. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P800002

Product / regulatory recordCompanyPathwayDecision dateSource
C.R. Bard, Inc.PMA approvalOct 24, 1980FDA
C.R. Bard, Inc.PMA supplementSep 29, 2026FDA

Explore the linked device profile

Other records with product code LMF

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

C.R. Bard, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
160 New Boston St., Woburn, MA, 01801

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records